Acelity licenses fat grafting technology from GID Group

Acelity has agreed a worldwide licensing deal with the GID Group for the Revolve System, a fat processing technology, to strengthen its plastic surgery portfolio.

Used in both reconstructive and cosmetic procedures to facilitate high-volume autologous fat grafting, Revolve is designed to yield rapid reliable results in high-volume procedures, through the use of a simple closed system that controls critical variables in the procedure.

Acelity subsidiary LifeCell has held exclusive rights to distribute Revolve in the US and Canada since 2013, with this new deal extending the agreement to include worldwide rights for developing, manufacturing and commercialising the device.

Fat grafting is a minimally-invasive procedure that removes fat from one part of the body and grafts it to another, delivering more natural outcomes in reconstructive and cosmetic procedures.

Dr Ron Silverman, chief medical officer at Acelity, said: "We are looking forward to working with the plastic surgery community to further develop the Revolve System and bring its clinical and economic benefits to patients around the world."

Acelity was created in September 2014 following Centaur Guernsey's decision to merge its subsidiaries KCI, LifeCell and Systagenix, with the combined organisation taking on the new Acelity name.